Literature DB >> 28244804

Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.

Susanne B Haga1, Jivan Moaddeb1, Rachel Mills1, Deepak Voora1.   

Abstract

AIM: To describe the rationale and design of a study evaluating the delivery of pharmacogenetic (PGx) testing in community pharmacies. Study rationale: Pharmacists have expressed interest in offering PGx testing; however, their lack of knowledge and experience, patients' acceptance and feasibility are unknown in this setting. STUDY
DESIGN: Through a cluster randomized trial, we will assess pharmacist and patient experiences with delivery of PGx testing as a standalone service or integrated into medication therapy management services. Anticipated results: We anticipate that PGx testing can be delivered in a community pharmacy setting and accepted and valued by patients.
CONCLUSION: This study is expected to provide valuable evidence about the real-world feasibility and acceptance of a community pharmacist-delivered approach of PGx testing.

Entities:  

Mesh：

Year:  2017        PMID： 28244804      PMCID： PMC5558549          DOI： 10.2217/pgs-2016-0175

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  51 in total

Review 1.  Economic effects of pharmacists on health outcomes in the United States: A systematic review.

Authors:  Marie A Chisholm-Burns; Joshua S Graff Zivin; Jeannie Kim Lee; Christina A Spivey; Marion Slack; Richard N Herrier; Elizabeth Hall-Lipsy; Ivo Abraham; John Palmer
Journal:  Am J Health Syst Pharm       Date:  2010-10-01       Impact factor: 2.637

2.  Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine.

Authors:  James S Green; Travis J O'Brien; Vincent A Chiappinelli; Arthur F Harralson
Journal:  Pharmacogenomics       Date:  2010-09       Impact factor: 2.533

3.  Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States.

Authors:  John E Murphy; James S Green; Laura A Adams; Robert B Squire; Grace M Kuo; Alan McKay
Journal:  Am J Pharm Educ       Date:  2010-02-10       Impact factor: 2.047

4.  Evaluation of a shared pharmacogenomics curriculum for pharmacy students.

Authors:  Kelly C Lee; Karen Suchanek Hudmon; Joseph D Ma; Grace M Kuo
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

5.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

Authors:  R Horne; J Weinman
Journal:  J Psychosom Res       Date:  1999-12       Impact factor: 3.006

6.  An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.

Authors:  Sudeep Karve; Mario A Cleves; Mark Helm; Teresa J Hudson; Donna S West; Bradley C Martin
Journal:  Med Care       Date:  2008-11       Impact factor: 2.983

7.  A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes.

Authors:  David Fox; L Douglas Ried; Gary E Klein; Wendy Myers; Kristen Foli
Journal:  J Am Pharm Assoc (2003)       Date:  2009 Mar-Apr

8.  Evaluation of a pilot medication therapy management project within the North Carolina State Health Plan.

Authors:  Dale B Christensen; Mary Roth; Troy Trygstad; John Byrd
Journal:  J Am Pharm Assoc (2003)       Date:  2007 Jul-Aug

9.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

10.  Delivering pharmacogenetic testing in a primary care setting.

Authors:  Rachel Mills; Deepak Voora; Bruce Peyser; Susanne B Haga
Journal:  Pharmgenomics Pers Med       Date:  2013-09-18
View more
  6 in total

1.  Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.

Authors:  Ahmet Kocael; Allison Pınar Eronat; Mete Bora Tüzüner; Ahmet Ekmekçi; Ahmet Lütfullah Orhan; İbrahim İkizceli; Hülya Yılmaz-Aydoğan; Oğuz Öztürk
Journal:  Mol Biol Rep       Date:  2019-02-02       Impact factor: 2.316

2.  Community pharmacy interventions for health promotion: effects on professional practice and health outcomes.

Authors:  Liz Steed; Ratna Sohanpal; Adam Todd; Vichithranie W Madurasinghe; Carol Rivas; Elizabeth A Edwards; Carolyn D Summerbell; Stephanie Jc Taylor; R T Walton
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

Review 3.  Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example.

Authors:  David F Kisor; Natasha J Petry; David R Bright
Journal:  Pharmgenomics Pers Med       Date:  2021-05-18

Review 4.  Community-Based Pharmacy Practice Innovation and the Role of the Community-Based Pharmacist Practitioner in the United States.

Authors:  Jean-Venable Goode; James Owen; Alexis Page; Sharon Gatewood
Journal:  Pharmacy (Basel)       Date:  2019-08-04

5.  Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb; Yiling Liu; Deepak Voora
Journal:  Pharmgenomics Pers Med       Date:  2021-07-15

6.  Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb; Yiling Liu; Deepak Voora
Journal:  Pharmgenomics Pers Med       Date:  2021-07-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.